Loading...
AstraZeneca Community
OM:AZN Community- 1 Narratives written by author
- 6 Comments on narratives written by author
- 227 Fair Values set on narratives written by author
Community Investing Ideas
Expect a future valuation of 22x as AstraZeneca bets on pipeline strength
Catalysts Most Immediate Catalyst (1–2 Years): Strong Oncology Portfolio Growth: AstraZeneca’s cancer drugs Tagrisso, Imfinzi, Enhertu, and Calquence continue gaining market share, driving double-digit revenue growth in oncology. Respiratory & Cardiovascular Expansion: New approvals and label expansions in Farxiga (diabetes/heart failure) and Tezspire (severe asthma) can drive meaningful sales upside.Read more
39users have liked this narrative
6users have commented on this narrative
117users have followed this narrative
UN
SEK 1.67k
0.5% overvalued intrinsic discount
Unike Fair Value
Revenue growth
8% p.a.
Profit Margin
28%
Future PE
22x
Share price in 2029
SEK 2.87k